Capricor Therapeutics(CAPR)
搜索文档
Capricor Therapeutics(CAPR) - 2021 Q1 - Earnings Call Transcript
2021-05-14 10:05
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants AJ Bergmann - Chief Financial Officer Linda Marbán - Chief Executive Officer Conference Call Participants Alan Leong - BioWatch News Operator Greetings. And welcome to Capricor Therapeutics First Quarter 2021 Earnings and Corporate Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions ...
Capricor Therapeutics(CAPR) - 2020 Q4 - Annual Report
2021-03-16 05:27
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2020 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-34058 CAPRICOR THERAPEUTICS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 88-0363465 (State or other jurisdiction of in ...
Capricor Therapeutics(CAPR) - 2020 Q4 - Earnings Call Transcript
2021-03-12 10:15
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2020 Earnings Conference Call March 11, 2021 4:30 PM ET Company Participants AJ Bergmann – Chief Financial Officer Linda Marbán – Chief Executive Officer Stephen Gould – Executive Consultant Conference Call Participants Michael Okunewitch – Maxim Group Emanuela Branchetti – H.C. Wainwright Alan Leong – BioWatch News Operator Greetings, and welcome to Capricor Therapeutics Fourth Quarter Full Year 2020 Earnings and Corporate Update Call. At this time, all particip ...
Capricor Therapeutics(CAPR) - 2020 Q3 - Quarterly Report
2020-11-14 06:15
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2020 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-34058 CAPRICOR THERAPEUTICS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 88-0363465 (State or other jurisdict ...
Capricor Therapeutics(CAPR) - 2020 Q3 - Earnings Call Transcript
2020-11-13 11:43
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2020 Earnings Conference Call November 12, 2020 4:30 PM ET Company Participants A.J. Bergmann - Chief Financial Officer Linda Marbán - President, Chief Executive Officer and Director Steve Gould - Executive Consultant Conference Call Participants Emanuela Branchetti - H.C. Wainwright Jason McCarthy - Maxim Group Alan Leong - BioWatch News Operator Greetings, and welcome to the Capricor Therapeutics Inc Third Quarter 2020 Earnings Call. [Operator Instructions]. As ...
Capricor Therapeutics (CAPR) Investor Presentation - Slideshow
2020-09-09 02:40
Corporate & Investor Presentation Capricor Therapeutics, Inc. Developing Transformative Therapies from Bench to Bedside NASDAQ: CAPR August 2020 Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulator ...
Capricor Therapeutics(CAPR) - 2020 Q2 - Quarterly Report
2020-08-10 20:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended June 30, 2020 or ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission File Number: 001-34058 CAPRICOR THERAPEUTICS, INC. (Exact Name Of Registrant As Specified In Its Charter) Delaware 88-0363465 (State or other jurisdiction o ...
Capricor Therapeutics(CAPR) - 2020 Q2 - Earnings Call Transcript
2020-08-09 18:22
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Anthony Bergmann - CFO & Corporate Treasurer Linda Marbán - Co-Founder, President, CEO & Director Conference Call Participants Naureen Quibria - Maxim Group Alan Leong - BioWatch Operator Greetings, and welcome to the Capricor Therapeutics Second Quarter 2020 Earnings Call. [Operator Instructions]. As a reminder, this conference is being recorded Thursday, August 6, 2020. I would now lik ...
Capricor Therapeutics(CAPR) - 2020 Q1 - Earnings Call Transcript
2020-05-18 23:34
Capricor Therapeutics Inc. (NASDAQ:CAPR) Q1 2020 Earnings Conference Call May 14, 2020 4:30 PM ET Corporate Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Emanuela Branchetti - H.C. Wainwright Alan Leong - BioWatch Operator Greetings and welcome to the Capricor Therapeutics Inc. First Quarter 2020 Earnings Conference Call. During the presentation, all participations will be in a listen-only mode. Afterward, we will conduct a question-and-answer session. [Operator Instructions ...
Capricor Therapeutics(CAPR) - 2020 Q1 - Earnings Call Presentation
2020-05-18 19:20
1 Capricor Q1 Earnings Call and Corporate Update May 14, 2020 Earnings Call NASDAQ: CAPR Forward-Looking Statements Statements in this presentation regarding the efficacy, safety, and intended utilization of Capricor's product candidates; the initiation, conduct, size, timing and results of discovery efforts and clinical trials; the pace of enrollment of clinical trials; plans regarding regulatory filings, future research and clinical trials; regulatory developments involving products, including the ability ...